Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection

• Main Authors: Matthew Sims (Author), Michael Silverman (Author), Thomas Louie (Author), Elaine Wang (Author), Colleen Kraft (Author), Mayur Ramesh (Author), Tatiana Bogdanovich (Author), Kelly Brady (Author), David Lombardi (Author), Asli Memisoglu (Author), Ananya De (Author), Brooke Hasson (Author), Christine Lee (Author), Paul Feuerstadt (Author), Darrell Pardi (Author), Colleen Kelly (Author), Peter Daley (Author), Godson Oguchi (Author), Barbara McGovern (Author), Lisa Von Moltke (Author)
• Format: Book
• Published: Cambridge University Press, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Antibiotics alone are often insufficient to treat recurrent C. difficile infection (rCDI) because they have no activity against C. difficile spores that germinate within a disrupted microbiome. SER-109, an investigational, oral, microbiome therapeutic comprised of purified Firmicutes spo...